I find it VERY interesting that this patent included a dual monkeypox/covid vaccine and was filed a YEAR and a half ago… US Patent Application #20210260182 – “Recombinant poxvirus based vaccine against SARS-CoV-2” – Feb 26, 2021
Monkey pox was created in 1958 when scientists were injecting smallpox into monkeys for research purposes in a lab in Denmark. Monkey pox made the jump to humans in 1971 when scientists used said monkey liver tissue in small pox vaccines throughout Africa.
Source:
https://www.cdc.gov/poxvirus/monkeypox/about.html
The company Tonix Pharmacuticals has been developing these sketchy ass covid vaccines using horsepox/monkeypox viruses since last year, never noticed in the patent they were even trying to make a dual bivalent covid/monkeypox vaccine… Here is the patent: https://patents.justia.com/patent/20210260182
Here is the site which has some updates on their new Poxvirus which is encoded for the new Omicron/BA2 spike proteins. Dang these guys are just fortue tellers! https://www.tonixpharma.com/tnx-1840-tnx-1850/:
TNX-1840 and TNX-1850 are planned new versions of the TNX-1800 vaccine that encode spike protein from SARS-CoV-2, omicron and BA.2 strains, respectively. TNX-1800 is a live attenuated modified horsepox virus vaccine that is designed to express the Spike protein of the SARS-CoV-2 virus and to elicit a predominant T cell response. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor.
You can just show people this paper if they say monkeypox can’t come from a lab.. “Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments”:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188453
We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches.
~
Tonix Pharmacuticals – This is one of their press releases from last October: https://stockhouse.com/news/press-releases/2021/10/15/tonix-pharmaceuticals-announces-ribbon-cutting-ceremony-for-its-infectious:
October 14 2022 “We at Tonix are excited to achieve this significant milestone in our efforts toward supporting and growing our pipeline of vaccines and antiviral therapeutics,” stated Dr. Lederman. “We believe that this strategy will enable Tonix to develop vaccines and therapeutics to address the current COVID-19 pandemic, and to be prepared to efficiently combat potential novel or emerging pathogens, termed ‘Disease X’, that could impact society in the future. We believe that the recombinant pox virus platform technology underlying TNX-1800 and TNX-801, coupled with our capabilities at the RDC and our Advanced Development Center (ADC) for manufacturing, will be rapidly deployable for addressing Disease X, with simplified distribution and administration, relative to modified mRNA-based vaccines. Our goal is to be able to design and test new recombinant pox virus vaccines against novel pathogens within the 100 days of recognition of a potential emerging pandemic threat, consistent with the criteria1,2 recently set forth by the White House Office of Science and Technology Policy.”
Tonix’s lead vaccine candidate for COVID-19, TNX-1800, is a live replicating vaccine based on Tonix’s recombinant pox vaccine (RPV) platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021 and expects to start a Phase 1 study in humans in the first half of 2022. TNX-1800 is an investigational new biologic and has not been approved for any indication. TNX-1800 is based on TNX-801, live horsepox virus vaccine for percutaneous administration, which is in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication.
~
FROM CDC-
“The first human case of monkeypox was recorded in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox”
So all our ‘HELP’ to vaccinate in the congo for smallpox… Created something that looks worse-
“Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments” – https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188453
Authors: Ryan S. Noyce, Seth Lederman, David H. Evans
Published: January 19, 2018
“We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches.”
Competing interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests: DHE and RDN provide consultation services to Tonix Pharmaceuticals Ltd. SL is the co-founder, CEO and chairman of Tonix Pharmaceuticals Ltd. A US patent application (Synthetic chimeric poxviruses; Application No.: 62/434,794; first provisional filed November 2, 2016) has been filed on behalf of the Governors of the University of Alberta and Tonix Pharmaceuticals claiming the three authors as co-inventors.
“DHE and RDN provide consultation services to Tonix Pharmaceuticals” DHE and RDN are abbreviations for David H. Evans and Ryan S. Noyce
synthetic chimeric poxvirues? https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188453 – “Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments”
Ten large (10–30 kb) fragments of DNA were synthesized based on the HPXV [Horsepox Virus] sequence along with two 157 nt VACV terminal sequences, and were recombined into a live synthetic chimeric HPXV (scHPXV) in cells infected with Shope fibroma virus (SFV). Sequencing of the 212 kbp scHPXV confirmed it encoded a faithful copy of the input DNA.
We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches.
The patent assignee is a company of a NY professor, Enzo Paoletti, who died in January 2018.
https://patents.justia.com/patent/20210260182
US Patent Application for RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS Patent Application (Application #20210260182)
Here’s some other patents by the same guy: https://patents.justia.com/inventor/ryan-noyce
Tonix Pharmaceuticals – For example, here is their TNX-1840 chimeric pox vaccine updated with omicron spike protien encoding.. https://www.tonixpharma.com/tnx-1840-tnx-1850/:
TNX-1840 and TNX-1850 are planned new versions of the TNX-1800 vaccine that encode spike protein from SARS-CoV-2, omicron and BA.2 strains, respectively.
TNX-1800 is a live attenuated modified horsepox virus vaccine that is designed to express the Spike protein of the SARS-CoV-2 virus and to elicit a predominant T cell response. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor.
TNX-1840/TNX-1850 is an investigational new biologic and has not been approved for any indication.
Here is press release from Oct 2021 explaining more: https://stockhouse.com/news/press-releases/2021/10/15/tonix-pharmaceuticals-announces-ribbon-cutting-ceremony-for-its-infectious:
TNX-1800 is an investigational new biologic and has not been approved for any indication.TNX-1800 is based on TNX-801, live horsepox virus vaccine for percutaneous administration, which is in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication.
The patent holder is Ryan Noyce, a research working for Tonix – https://patents.justia.com/inventor/ryan-noyce
University of Alberta researchers launched a joint effort with U.S.-based Tonix Pharmaceuticals to develop and test a vaccine against COVID-19.
The researchers hope their unique delivery method for the vaccine-synthetic vaccinia and horsepox viruses-will prove more effective than others being tested around the world.“Poxviruses, such as vaccinia and horsepox, are a good vaccine platform for delivering the antigens that are needed to invoke an immune response against a virus like SARS-CoV-2,” said David Evans, a U of A virologist and professor of medical microbiology and immunology.
“These antigens are SARS-CoV-2 proteins that the poxvirus has been engineered to make and supply for processing by the immune system. The idea is that these recombinant proteins might give you a better antigenic response-and hopefully in the place where it’s most needed.”
